Gemfibrozil is a class of pharmaceutical drugs prescribed for lowering lipid levels (hypercholesterolemia) in the human body. Abnormally high levels of cholesterol may form fatty deposits (plaque) in the walls of arteries. In case the plaque bursts it could lead to a blood clot.
This increases the risk of heart disease and stroke. Another adverse effect of hypercholesterolemia is its role in bile imbalance, leading to gallstones. It could also block blood flow to kidneys and stomach. Such occurrence, causing nausea, vomiting, abdominal pain, etc., is referred to as intestinal ischemic syndrome.
Hectic urbanized lifestyles, work stress, sedentary jobs, lack of exercise, and improper dietary habits are observed to contribute to widespread prevalence of hypercholesterolemia across the globe. This is anticipated to be the key driver of the Gemfibrozil industry.
China is the most populous country in the world. Growing urbanization, economic stability, rising disposable incomes and increasing adaption of a westernized lifestyle including consumption of fast food and processed meals are contributing to higher affliction rates of hypercholesterolemia.
Main types of cholesterol lower medicines include CETP Inhibitors, ApoB Inhibitors, PPAR Agonists, MTTP Inhibitors, and PCSK9 Inhibitors. Statins are the commonly-prescribed drugs. They lower bad cholesterol by inhibiting an enzyme HMG-CoA reductase.
Gemfibrozil belongs to the fibrate category of drugs. It reduces the amount of fat produced by the liver. However, it may not lower the risk of stroke or heart attack. For the medication to work more effectively, it needs to be combined with lifestyle changes that include weight-loss, low-fat diet, exercise, abstinence from smoking and alcohol.
Moreover, like several allopathic drugs, Gemfibrozil is associated with certain side effects. These range from mild (upset stomach, unusual taste) to serious (infection, irregular heartbeat, allergic reaction).
Gemfibrozil when co-administered with cerivastatin leads to rhabdomylosis – a fatal condition. Rising popularity of alternative treatment approaches such as yoga, ayurveda, homeopathy, acupuncture, naturopathy, etc. could also have an adverse impact on gemfibrozil industry.
North America (especially U.S.), Europe, Japan and China are important regional markets in the gemfibrozil industry. Over 13 million Americans are on some cholesterol-lowering therapy. This is indicative of favorable growth prospects for North America from 2015 to 2020.
Famed manufacturers in the gemfibrozil industry are Abbott Healthcare, Sun Pharmaceuticals, Pfizer Inc., Taizhou Belucky Co. Ltd., Comwin International Co. Ltd., and Hitom Chemicals Co. Ltd.
Download Sample Request:
http://www.radiantinsights.com/research/global-and-chinese-gemfibrozil-industry-2015-market-research-report/request-sample
Table of Contents:
Chapter One Introduction of Gemfibrozil Industry
1.1 Brief Introduction of Gemfibrozil
1.2 Development of Gemfibrozil Industry
1.3 Status of Gemfibrozil Industry
Chapter Two Manufacturing Technology of Gemfibrozil
2.1 Development of Gemfibrozil Manufacturing Technology
2.2 Analysis of Gemfibrozil Manufacturing Technology
2.3 Trends of Gemfibrozil Manufacturing Technology
This increases the risk of heart disease and stroke. Another adverse effect of hypercholesterolemia is its role in bile imbalance, leading to gallstones. It could also block blood flow to kidneys and stomach. Such occurrence, causing nausea, vomiting, abdominal pain, etc., is referred to as intestinal ischemic syndrome.
Hectic urbanized lifestyles, work stress, sedentary jobs, lack of exercise, and improper dietary habits are observed to contribute to widespread prevalence of hypercholesterolemia across the globe. This is anticipated to be the key driver of the Gemfibrozil industry.
China is the most populous country in the world. Growing urbanization, economic stability, rising disposable incomes and increasing adaption of a westernized lifestyle including consumption of fast food and processed meals are contributing to higher affliction rates of hypercholesterolemia.
Main types of cholesterol lower medicines include CETP Inhibitors, ApoB Inhibitors, PPAR Agonists, MTTP Inhibitors, and PCSK9 Inhibitors. Statins are the commonly-prescribed drugs. They lower bad cholesterol by inhibiting an enzyme HMG-CoA reductase.
Gemfibrozil belongs to the fibrate category of drugs. It reduces the amount of fat produced by the liver. However, it may not lower the risk of stroke or heart attack. For the medication to work more effectively, it needs to be combined with lifestyle changes that include weight-loss, low-fat diet, exercise, abstinence from smoking and alcohol.
Moreover, like several allopathic drugs, Gemfibrozil is associated with certain side effects. These range from mild (upset stomach, unusual taste) to serious (infection, irregular heartbeat, allergic reaction).
Gemfibrozil when co-administered with cerivastatin leads to rhabdomylosis – a fatal condition. Rising popularity of alternative treatment approaches such as yoga, ayurveda, homeopathy, acupuncture, naturopathy, etc. could also have an adverse impact on gemfibrozil industry.
North America (especially U.S.), Europe, Japan and China are important regional markets in the gemfibrozil industry. Over 13 million Americans are on some cholesterol-lowering therapy. This is indicative of favorable growth prospects for North America from 2015 to 2020.
Famed manufacturers in the gemfibrozil industry are Abbott Healthcare, Sun Pharmaceuticals, Pfizer Inc., Taizhou Belucky Co. Ltd., Comwin International Co. Ltd., and Hitom Chemicals Co. Ltd.
Download Sample Request:
http://www.radiantinsights.com/research/global-and-chinese-gemfibrozil-industry-2015-market-research-report/request-sample
Table of Contents:
Chapter One Introduction of Gemfibrozil Industry
1.1 Brief Introduction of Gemfibrozil
1.2 Development of Gemfibrozil Industry
1.3 Status of Gemfibrozil Industry
Chapter Two Manufacturing Technology of Gemfibrozil
2.1 Development of Gemfibrozil Manufacturing Technology
2.2 Analysis of Gemfibrozil Manufacturing Technology
2.3 Trends of Gemfibrozil Manufacturing Technology
No comments:
Post a Comment